Table 1.

National recommendations

Recommendation	Online publication date	Print publication date	Recommended screening practice
1FDA Dear Healthcare Professional Letter	7/12/2004	Online only	Screen patients at high risk of HBV infection before initiation of rituximab therapy. Closely monitor carriers of HBV for clinical and laboratory signs of active HBV infection and for signs of hepatitis during and for up to several months after rituximab therapy.
2AASLD	1/26/2007	2/2007	Screen patients at high risk for HBV infection prior to immunosuppressive therapy.
			Test with HBsAg.
3CDC	9/19/2008	9/19/2008	Screen all patients prior to immunosuppressive therapies.
			Test with HBsAg, anti-HBc, and anti-HBs.
4AASLD Update	7/28/2009	9/2009	Screen patients at high risk for HBV infection prior to immunosuppressive therapy.
			Test with HBsAg and anti-HBc.
5NCCN	8/28/2009	Online only	Screen cancer patients with lymphoid malignancies, patients who have spent significant time in HBV-endemic areas or have risk factors for HBV infection, and patients anticipating intensive immunosuppressive therapy.
			Test with HBsAg, anti-HBc, and anti-HBs.
6IOM	1/11/2010	1/11/2010	Screen patients with HBV risk factors.
			Test with HBsAg.
7ASCO	6/1/2010	7/1/2010	Screen cancer patients at high risk for HBV infection or anticipating highly immunosuppressive therapy such as stem cell transplantation or rituximab therapy.
			Test with HBsAg and in some cases also with anti-HBc.

Abbreviations: AASLD American Association for the Study of Liver Diseases, ASCO American Society of Clinical Oncology, CDC Centers for Disease Control and Prevention, FDA Food and Drug Administration, IOM Institute of Medicine, NCCN National Comprehensive Cancer Network, HBsAg Hepatitis B surface antigen, anti-HBc Antibody to hepatitis B core antibody, anti-HBs Antibody to hepatitis B surface antigen.